Beta-IV spectrin antibody | knockout validation | Merck Millipore MABN1727

This is a knockout-validated antibody summary, based on the publication "Postnatal Development of Spasticity Following Transgene Insertion in the Mouse βIV Spectrin Gene (SPTBN4)", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Mouse monoclonal IgG2bκ

Company: Merck Millipore

Antibody: Beta-IV spectrin

Catalog number: MABN1727

Summary: Mouse monoclonal IgG2bκ against a recombinant fusion fragment corresponding to 192 amino acids from the C-terminal half of human beta-IV spectrin. Reacts with human and rat. It is predicted to react based on 100% sequence homology with mouse. Suitable for western blot and immunohistochemistry.

Validation Method

Western blot

Sample

Brain lysates from wildtype, SPTBN4+/– (L25+/–) and SPTBN4–/– (L25+/+) mice.

Figure

Representative western blot of brain lysates from wildtype (WT), unaffected transgenic (L25+/–) or affected transgenic (L25+/+) mice probed for IV spectrin. Wild-type brain lysates reveal strong labelling for IV spectrin, while brains of the affected (L25+/+) mice showed no bands. Diminished bands are evident for L25+/– mouse brains. GAPDH labeling of the same samples demonstrated equal loading and transfer of protein. Please see Figure 3 in the article [1].

Clone note

The same clone (N393/76) is sold as Neuromab 73-377, 75-377; EMD Millipore MABN1727.

References
  1. Kichkin E, Visvanathan A, Lovicu F, Shu D, Das S, Reddel S, et al. Postnatal Development of Spasticity Following Transgene Insertion in the Mouse βIV Spectrin Gene (SPTBN4).. J Neuromuscul Dis. 2017;4:159-164 pubmed publisher